Overview: Acylcarnitine C2 TestIntroduction: The Acylcarnitine C2 Test screens for fatty acid oxidation disorders, which prevent your body from breaking down fats for energy, potentially causing low blood sugar, muscle weakness, or severe fatigue, especially during illness. Affecting 1 in 10,000 newborns, these disorders are critical in pediatric care, with diagnostic challenges during asymptomatic periods, particularly in preterm infants or those with mild symptoms. Following 2023 ACMG guidelines, it uses tandem mass spectrometry (MS/MS) for high specificity, supporting metabolic screening. This test is vital for diagnosis, treatment planning, and improving outcomes in biochemistry, aiming to prevent sudden death during fasting or infection.
Other Names: C2 Assay, Acetylcarnitine Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for precision.
Historical Milestone: Acylcarnitine testing began in the 1990s with newborn screening by Donald Chace, focusing on fatty acid metabolism defects. Tandem MS advancements in the 2000s by Applied Biosystems enhanced detection of C2 carnitine, surpassing earlier high-performance liquid chromatography (HPLC) methods that lacked resolution for newborn screening.
Purpose: Measures C2 acylcarnitine levels to diagnose fatty acid oxidation disorders, guides dietary management with medium-chain triglycerides and carnitine supplementation, and evaluates patients with hypoglycemia, muscle weakness, or metabolic crises, aiming to avoid life-threatening episodes during illness or fasting.
Test Parameters: C2 acylcarnitine levels
Pretest Condition: Fasting preferred for 6-8 hours to assess baseline metabolism and detect abnormalities. Collect dried blood spot, plasma, or serum. Report history of hypoglycemia, weakness, or recent infections.
Specimen: Dried Blood Spot (filter paper, 3-5 spots), Plasma (NaHep, 2-4 mL), Serum (SST, 2-5 mL); 2 mL plasma in Na Heparin tube or dried blood spot on filter paper. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document hypoglycemia, muscle weakness, or illness history. Include dietary habits, exercise patterns, or family history of metabolic disorders, noting any recent fasting or viral exposure.
Consent: Written consent required, detailing the test's purpose, fatty acid disorder risks (e.g., rhabdomyolysis, sudden death), and potential risks of sample collection, emphasizing neonatal screening benefits and long-term management.
Procedural Considerations: Uses tandem mass spectrometry (MS/MS) to measure C2 levels, requiring laboratories with Waters Quattro Premier systems and trained technicians to handle dried blood spots. Results are available in 2-3 days, supporting neonatal care. Performed in labs with sample drying protocols and humidity control to prevent degradation and ensure accurate metabolite detection.
Factors Affecting Result Accuracy: Improper drying, contamination with skin oils, or exposure to heat can affect results. Fasting status, medications, or concurrent illness may alter levels, necessitating controlled conditions and clinical correlation to avoid misdiagnosis.
Clinical Significance: Elevated C2 confirms fatty acid oxidation disorders, guiding carnitine supplementation and cornstarch therapy to maintain blood glucose. A child with early treatment might avoid hypoglycemic coma, while untreated cases can lead to cardiac arrest or developmental delays. Normal levels may require genetic testing (e.g., CPT1A) to rule out carriers or alternative diagnoses.
Specialist Consultation: Consult a metabolic specialist or pediatrician for result interpretation and management, particularly for infants or those with family history, where dietary adjustments and emergency plans are critical to prevent crises.
Additional Supporting Tests: Urine organic acids, CPT2 gene analysis, or acylcarnitine profile to confirm diagnosis and assess enzyme function, aiding in personalized care and monitoring long-term outcomes.
Test Limitations: Non-specific for disorder type (e.g., CPT1 vs. CPT2); clinical correlation with symptoms and genetics is needed. Sensitivity varies with age and fasting state, requiring repeat testing during symptomatic periods.
References: ACMG Guidelines, 2023; Journal of Pediatrics, Rinaldo P, 2022.
